Smart Technology Facilitated Patient-centered Venous Thromboembolism Management (SmaVTE-RCT)

Navy General Hospital, Beijing

Status: Invitation-only

Conditions: Venous Thromboembolism; Digital Health; Health Education

Treatments: Other: mobile venous thromboembolism application (mVTEA)

Study type: Interventional

Funder types: Other

Identifiers

NCT06350331

HZKY-PJ-2024-8-1

Details and patient eligibility

About

Smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management. These technologies have the potential to be applied in disease pre-warning, decision-making support, health education, and healthcare maintenance. They are expected to address the challenges in managing thrombosis, improve access to high-quality medical resources in various regions, and enhance the development of a network for thrombosis rescue and treatment prevention.

The objective of this study is to evaluate the impact of mobile venous thromboembolism application (mVTEA) based patient-centered management of venous thromboembolism (VTE) on patients' perceptions of thromboprophylaxis, in order to enhance clinical practice and establish a foundation of evidence for managing patients with VTE.

Enrollment: 256 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Inpatients ≥18 years of age at admission;
• Previous or current definitive diagnosis of DVT and/or PE by imaging, or at high risk of VTE at discharge: Padua score ≥4 for medical patients and Caprini score ≥5 for surgical patients.
• Signed informed consent

Exclusion criteria

• Mental disorder or combination of other serious diseases leading to incapacity for independent living;
• Inability to use smartphones, computer tablets and other smart devices;
• Being pregnant or breastfeeding;
• Have participated in similar trials or are undergoing other clinical trials.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

256 participants in 2 patient groups

mVTEA Management Group

Experimental group

Description:

Patients randomly assigned to the mVTEA management group will be discharged with mVTEA-assisted patient-centered VTE management.

Treatment:

Other: mobile venous thromboembolism application (mVTEA)

Routine Management Group

No Intervention group

Description:

Patients randomly assigned to the routine management group will be given routine post-discharge management in accordance with local clinical practice.